New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines' ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis (Businesswire) - May 19, 2024 - P2a | N=41 | NCT04968574 | Sponsor: Endeavor Biomedicines, Inc. | "Key findings from the ENV-101 Phase 2a clinical trial in IPF presented today at the ATS 2024 International Conference include: Patients who received ENV-101 experienced a statistically significant improvement in lung function through the 12 weeks of the trial, with a 1.9% mean improvement in percent predicted forced vital capacity (ppFVC) from baseline as compared to a mean decline in ppFVC of 1.3% for patients in the placebo group (P=0.035). Patients who received ENV-101 showed a statistically significant increase in total lung capacity (TLC) above baseline at 12 weeks with a 200 mL mean increase as compared to a mean decline of 56 mL for patients who received placebo (P=0.005).....Endeavor BioMedicines intends to initiate the Phase 2 WHISTLE-PF (Wound-remodeling Hedgehog-inhibitor ILD Study Testing Lung Function Endpoints -PF) trial."
New P2 trial • P2a data • Idiopathic Pulmonary Fibrosis
|